Amphastar Pharmaceuticals, Inc. (AMPH) is a publicly traded Healthcare sector company. As of May 21, 2026, AMPH trades at $17.36 with a market cap of $758.40M and a P/E ratio of 10.47. AMPH moved +1.35% today. Year to date, AMPH is -32.34%; over the trailing twelve months it is -27.88%. Its 52-week range spans $16.65 to $53.96. Analyst consensus is neutral with an average price target of $22.00. Rallies surfaces AMPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Amphastar Q1 EPS Drops to $0.42, Misses Consensus by $0.28: Amphastar’s first-quarter EPS came in at $0.42, missing the consensus estimate by $0.28 and down from $0.74 a year earlier. The significant shortfall to the $0.70 consensus highlights a sharp earnings decline that could pressure the stock as investors reevaluate growth prospects.
| Metric | Value |
|---|---|
| Price | $17.36 |
| Market Cap | $758.40M |
| P/E Ratio | 10.47 |
| EPS | $1.71 |
| Dividend Yield | 0.00% |
| 52-Week High | $53.96 |
| 52-Week Low | $16.65 |
| Volume | 4 |
| Avg Volume | 0 |
| Revenue (TTM) | $720.53M |
| Net Income | $79.23M |
| Gross Margin | 47.34% |
6 analysts cover AMPH: 0 strong buy, 0 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $22.00.